About Sebacia

Company Overview
and Mission

Founded in 2010 as part of The Innovation Factory (www.TIF.net), Sebacia set out to develop an alternative to the topical and systemic drugs currently available for the treatment of acne. Starting with the theory that several acne technologies have shown the ability to treat acne by eliminating or modifying the sebaceous gland but were limited by safety concerns or long, painful procedures, Sebacia envisioned a highly selective, targeted procedure to photothermally affect change in the sebaceous gland.

Sebacia leveraged the potential of microparticles — long-studied in several areas of medical research, including tumor ablation — and laser energy to formulate a topical solution for acne. The intention was to develop a system designed to deliver particles into the gland that could be calibrated to absorb wavelengths of laser light and avoid absorption into the skin. Thus, potentially, selectively heating only the targeted skin structures that are involved in acne.

We believe that these microparticles, topically delivered to the skin, offer the potential to address a number of dermatologic conditions affecting millions of lives daily.

Our Core Team

Our diverse management group utilizes deep, early stage experience in the active guidance of the company. With a focus on aggressive market introduction and expertly handled economics, the collective blends the best of established practices with new innovations in business development.


Chuck Abraham, CEO

Chuck was recruited to manage the commercial launch of the product after the company’s successful completion of European and U.S. clinical trials, CE Mark and FDA Registration.

Most recently Chuck lead OraMetrix, Inc. to a successful commercialization of its products and services with a cloud-based business model providing custom Orthodontiic appliances to doctors for use in patients. Chuck's additional experience includes commercialization of medical products and services.

Prior positions include leadership roles with OraMetrix, Inc., eMerge Interactive, Nellcor Puritan Bennet, and General Electric Medical Systems.

Chuck attended Mississippi State University and received a Bachelor of Science in Biological/Biosystems Engineering.

Todd Meyer, COO and General Counsel

Prior to his role as COO and General Counsel of Sebacia, Todd spent three years as the program manager for Halscion, Inc. while it was a portfolio company at The Innovation Factory. He also served as an associate within Gunderson Dettmer’s corporate transactions and intellectual property group and held pharmaceutical sales and marketing positions with both Astra USA and Abbott Laboratories.

Todd has been representing and working with life science technologies for more than 18 years. Currently, he is a member of the American Academy of Dermatology (AAD), Southeastern Medical Device Association (SEMDA), and the Association of University Technology Managers (AUTM). He is also a non-active member of the Massachusetts Bar.

When he's not coaching one of his two boys' lacrosse teams, Todd can be found sharpening his knife skills in the kitchen or twirling his Terrible Towel™ during Pittsburgh Steelers games.

Dilip Paithankar, Ph.D., CTO

Dilip has served as Chief Technology Officer for Sebacia since the founding of the company. Prior to this role, he served as the VP of Research and Development at Cellutions, a startup company within the Innovation Factory. This position was preceded by research and product development roles at Candela Corporation, a leading laser dermatology company and a focus on laser-based diagnostic methods at Wellman Center for Photomedicine (MGH) and Purdue University.

A fellow of the American Society of Lasers in Surgery and Medicine, Dilip has been working with medical device technology and development for more than 17 years.

In his spare time, Dilip can be found coaching his kids' soccer teams and working on his Table Tennis loop shot.

Robert Leslie, CFO

Bob has served as CFO of Sebacia since the company's inception. He is presently the Vice President of Finance and Administration at The Innovation Factory (TIF), assuming the role of CFO-in-residence of current and former TIF portfolio companies, including Halscion, Inc., Novalign, Inc., AqueSys, Inc., and Cellutions, Inc.

Before joining Sebacia, he held senior financial management positions with several venture capital (VC)-financed technology and manufacturing companies. He also served as Chief Financial Officer of Cordova Ventures, a VC firm located in Atlanta, Georgia. Bob maintains a Certified Public Accountant’s license in the state of Texas.

An avid long distance runner, Bob has completed six full marathons and 20+ half marathons. He also enjoys physical fitness and watching Major League Baseball.

Cory Anderson, VP, Clinical Marketing and Business Development

Cory is responsible for business development, European post approval studies, and commercial launch activities in Europe for the Sebacia Acne Treatment. Since starting with The Innovation Factory (TIF) over 10 years ago, he has worked in a variety of roles in TIF and TIF’s portfolio companies. These positions include his current role with Sebacia, VP of Business Development for TIF, and Program Manager for both AqueSys and NeoVista. Additionally, Cory is a Principal at Accuitive Medical Ventures. He currently serves as an observer on the MyoScience board and formerly served as an observer on the Aquesys board (acquired by Allergan).

Cory earned his MBA from Emory University and both his Bachelor and Master degrees in Biomedical Engineering from Tulane University.

In his spare time, Cory enjoys spending time with his two young children, playing tennis, and experimenting with different dishes in the kitchen.

Gretchen Richards, VP, Clinical & Regulatory Affairs

Gretchen recently joined Sebacia to lead clinical development and regulatory affairs. After earning a Master’s Degree in Molecular Biology, she spent a short time as a research scientist in academia before making the transition to the biopharmaceutical industry. Over the past 25 years, Gretchen has advanced numerous medical products through early-stage development to proof of concept and pivotal trials. She played an integral role in leading late-stage clinical trials of Velcade® (Takeda Millennium Pharmaceuticals) and Kalbitor® (Dyax Corporation).

Prior to joining Sebacia, Gretchen led clinical research and program teams at several biopharmaceutical startup organizations including Molecular Insight Pharmaceuticals, Nucryst Pharmaceuticals, MacroChem Corporation and Hybridon, Inc. She has also held clinical operations positions at two contract research organizations. As a result, Gretchen’s development experience spans a wide variety of therapeutic areas and includes investigational drugs, biologics and medical devices.

Gretchen lives with her husband and their Jack Russell Terrier, Oliver. She enjoys swimming, hiking, kayaking, playing ball with Oliver and most things that allow her to enjoy the outdoors.

Richard Blomgren, Director, Quality

Richard has been the guiding force for Sebacia Quality and Manufacturing, as part of The Innovation Factory (TIF) management team. In his role as Director of Quality Systems for TIF for the past 12 years, Richard brings more than 20 years expertise in quality, manufacturing, and product development. During his time at TIF, Richard has created and managed quality systems for 10 medical startup companies and helped to successfully transition 7 of these companies out of TIF.

Prior to joining TIF, Richard held quality management and quality engineering positions at Teleflex Medical (formerly Rüsch), MMG Healthcare, GEC Marconi Avionics, and Rockwell International.

Away from work, Richard enjoys hiking and camping with his four sons and volunteers as an Assistant Scoutmaster for their local Boy Scout troop.

Pedro Medrano, VP, Engineering & Program Management

Pedro recently joined Sebacia to lead engineering and commercialization readiness projects. After earning a B.S. Degree in Materials Science & Engineering, he spent time researching high-energy density capacitors for use in numerous applications, including Implantable Defibrillators. During his 15 years at St. Jude Medical, Inc., Pedro led numerous global, cross-functional teams in the development of Class III implantable devices and systems.

Prior to joining Sebacia, Pedro was the Director of the Project Management Office for Philips’ Nuclear Medicine/Imaging business, where he was responsible for New Product Development and Sustaining programs. He has also held Business Development positions with Novartis’ Eyecare Division (CIBAVISION/Alcon) and The Innovation Factory, where he performed due diligence on refractive laser surgery, Intraocular and Contact Lenses, and drug delivery devices.

In his spare time, Pedro enjoys participating in and watching all types of sports with his 3 boys.


Neal Walker, DO
A Board-certified dermatologist and serial entrepreneur with over 18 years of experience in the biopharmaceutical industry, Neal is the current President and CEO of Aclaris Therapeutics. Prior to founding Aclaris, he was co-founder, President, and CEO of Vicept Therapeutics (acquired by Allergan).

Neal has co-founded and led a number of life science companies: Octagon Research Solutions, a software and services provider to biopharmaceutical companies (acquired by Accenture); Trigenesis Therapeutics, a specialty dermatology company (acquired by Dr. Reddy's Laboratories) where he served as Chief Medical Officer; and Cutix Inc., a commercial dermatology company that markets PreSun®, a sunscreen brand acquired from Bristol-Myers Squibb. He began his pharmaceutical industry career at Johnson & Johnson.

Neal received his MBA from The Wharton School at the University of Pennsylvania.

John Dyett
John is a Founder of Salem Partners and Salem Partners Wealth Management. He heads the firm's efforts in the Life Sciences. John has raised over $500 million of equity and completed multiple M∓A transactions for Salem Partners’ clients. John helped raise several rounds of financing for Adams Respiratory (acquired by Reckitt Benckiser) and ZS Pharma (acquired by AstraZeneca). Prior to founding Salem Partners, John was a banker with Gerard Klauer Mattison & Co., Inc. and Needham and Co., Inc. John serves on the Board of Directors of Femasys, Inc., Sebacia, Inc., OncoNano Medicine, Inc. and the Sierra Total Return Fund. John also serves on the Board of Trustees of Middlesex School in Concord, MA. John is a graduate of Harvard College.

Beckie Robertson
With nearly 25 years of venture capital and operating experience in medical products as an engineer, entrepreneur, corporate executive, and investor, Beckie is the resident specialist in early-stage investing in medical devices and diagnostics at Versant Ventures.

Beckie has held multiple executive-level positions in preeminent healthcare-based companies, including Chiron Diagnostics where she headed business development; Egis, an IVP portfolio company; and Lifescan, a Johnson & Johnson Company where she specialized in operations and finance, helping grow the organization from an early-stage venture-funded company to a worldwide market leader in diabetes diagnostics.

Thomas D. Weldon
As a co-founder and Chairman of The Innovation Factory (TIF) and Novoste Corporation and co-founder of Accuitive Medical Ventures, Tom brings over 25 years of operating experience, critical fundraising skills, and IPO-insight in the medical device industry to Sebacia.

Through his role at TIF, Tom has co-founded numerous companies including: AcuFocus, AqueSys, Halscion, Liposonix, Neuronetics, and most recently, Sebacia. He is also resides on the Board for MyoScience, Respicardia, and Sebacia.

Among his many accomplishments, Tom holds more than 20 US patents on medical devices. He received his MBA from Indiana University and a B.S. in Industrial Engineering from Purdue University.

Gerard van Hamel Platerink
Private equity investments, business development, corporate communications, research analysis...these are all areas of specialty that Gerard has culled over the past decades. Currently a Managing Director with Redmile Group, a San Francisco-based healthcare investment fund, Gerard rounds out our Board of Directors with financial savvy and business finesse.

Notably, in his role as an equity research analyst with Salomon Brothers (now Citigroup) in London, he was an integral member of the #1 ranked healthcare research team.

Gerard brings a multinational perspective to the Sebacia Board. He is a Dutch national, was born in Borneo in Southeast Asia, grew up in Africa, and was educated in the UK where he received his MBA from Cambridge University and his B.S. in Physics from St. Andrews University.

Jesse Treu, Ph.D.
Jesse has been a Partner of Domain since its inception in 1985. He has been a director of 37 early-stage healthcare companies, 23 of which have so far become successful public companies.

Present board memberships include Afferent Pharmaceuticals, Aldeyra Therapeutics, CoLucid Pharmaceuticals, RightCare Solutions, Sebacia, Tandem Diabetes Care, Veracyte and Xagenic. He has served as a founder, president and chairman of numerous venture stage companies.

Prior to the formation of Domain, Jesse was vice president of the predecessor organization to The Wilkerson Group, and its venture capital arm, CW Ventures. While at CW Ventures, he served as president and CEO of Microsonics, a pioneer in computer image processing for cardiology. Previous to that, Jesse held executive positions at Technicon Instruments Corporation (now Siemens Medical Solutions Diagnostics) and at GE. He received his B.S. in physics from Rensselaer Polytechnic Institute and his M.A. and Ph.D. in physics from Princeton University.


Caleb Smith
Caleb joined Salem Partners in 2007 and is focused on sourcing, evaluating and structuring transactions in the healthcare & life sciences sectors. While at Salem, he has been directly involved with companies such as Exemplar Pharma (sold to Allergan), Femasys (private), Neos Therapeutics (Nasdaq: NEOS), OncoNano Medicine (private), Sebacia (private) and ZS Pharma (sold to AstraZeneca). Before joining Salem, Mr. Smith was a director at Harvey & Company, a leading merchant banking firm based in Newport Beach. Prior to Harvey & Company, he was a consultant with Public Health Foundation Enterprises and performed clinical research at Los Angeles County + USC Medical Center. Caleb graduated with a Bachelor of Science from the University of Southern California.

Carl Berke, Ph.D.
Carl, a Partner at the Innovation Fund, has curated a career that has spanned over 25 years in the practice and management of innovation. With each new endeavor, he continues to fulfill his lifelong goal of bringing new consumer and professional technologies from lab to market. To date, he has been a primary inventor on six US patents.

In addition to his hands-on dedication to new technologies, prior professional commitments included serving as a Partner at Integral/Analysis Group, a consulting firm, focusing on the management of innovation and growth strategy, and as a private equity investor as a member of Angel Healthcare Investors LLC. He has served on the Boards of Quosa (research literature management software), Kasalis (robotics), Combinent (women's health), Infobionic (cardiac monitoring), and the Sudanese Education Fund (philanthropy).

Carl also holds an appointment as Lecturer in the Biomedical Enterprise Program in the Harvard-MIT Division of Health Sciences and Technology.

Carl received his Ph.D. in Organic Chemistry from the University of California at Berkeley and an A.B. from Cornell University.


Todd C. Brady, M.D., Ph.D.
Chief Executive Officer, President & Director; Aldeyra Therapeutics
Dr. Brady has more than 18 years of pharmaceutical clinical and business development experience. Prior to joining Aldeyra as president and CEO in 2011, Dr. Brady was an entrepreneur-in-residence and principal at Domain Associates, where he led institutional financing in numerous biotechnology companies from 2004 to 2013. Dr. Brady was instrumental in the initial funding of Sebacia while at Domain.

Prior to joining Domain, Dr. Brady was a co-founder and CEO of Phenome Sciences, a biotechnology firm he merged with Xanthus Pharmaceuticals (acquired by Antisoma), where he was later executive vice president of Strategic Development and Planning. Dr. Brady also worked as head of business development and medical director at Aderis Pharmaceuticals (acquired by Schwarz Pharma, now part of UCB).

While at Xanthus and Aderis, Dr. Brady was a medical consultant on numerous pre-clinical programs and clinical programs in Phases I through IV, including Neupro®, a drug now marketed for Parkinson’s Disease. Dr. Brady holds an M.D. from Duke University Medical School, a Ph.D. from Duke University Graduate School, and an A.B. from Dartmouth College.

Medical Advisory Board:

R. Rox Anderson, M.D.
Rox is an accomplished clinician, researcher, and inventor who has conceived and developed many of the non-scarring laser treatments now widely used in medical care. His research has advanced the basic knowledge of human skin photobiology, drug photosensitization mechanisms, tissue optics, and laser-tissue interactions.

Active research includes diagnostic tissue imaging and spectroscopy, photodynamic therapy, mechanisms of selective laser-tissue interactions, adipose tissue biology, and novel therapy for skin disorders.

Rox completed his dermatology residency and an NIH research fellowship at Harvard University and then joined the faculty where he is now Harvard Medical School Professor in Dermatology, Director of the Wellman Center for Photomedicine. He also serves as Adjunct Professor of Health Sciences and Technology at MIT.

Additionally, he teaches at Harvard and MIT and practices dermatology at Massachusetts General Hospital.

Among his roster of accomplishments, Rox has been awarded over 60 national and international patents, and has co‑authored over 300 scientific books and papers. He graduated from MIT and then received his M.D. magna cum laude from the joint MIT-Harvard medical program, Health Sciences and Technology.

Arielle N.B. Kauvar, M.D.
Dr. Kauvar, an internationally renowned board certified dermatologist, laser surgeon and Mohs (skin cancer) surgeon, is founding director of New York Laser & Skin Care. She has been helping patients reveal and maintain their healthiest skin for over 18 years. As a leading authority on laser surgery, cosmetic dermatology and skin cancer, she lectures nationally and internationally, writes extensively and is frequently interviewed by media.

Dr. Kauvar's philosophy of using minimally invasive procedures for maximum skin care results and long term benefits is the cornerstone of her successful Manhattan practice. She is the author of over 100 papers and book chapters, including a comprehensive textbook on laser surgery. A graduate of Princeton University, Dr. Kauvar received her medical degree from Harvard Medical School and the Massachusetts Institute of Technology. She completed her dermatology residency at New York University Medical Center, where she is currently a Clinical Professor of Dermatology, followed by a fellowship in Mohs micrographic surgery and laser surgery. She currently serves on the Board of Directors of the American Society for Dermatologic Surgery and has previously served on the board of the American Society for Laser Medicine and Surgery and the American Society for Cosmetic Dermatology and Aesthetic Surgery. She is a past president of the Dermatologic Society of Greater New York. Additionally, Dr. Kauvar serves on the editorial boards of several medical journals and on the advisory boards of pharmaceutical and medical technology companies.

A native New Yorker, Dr. Kauvar developed an early interest in art and science. Prior to completing her medical studies she spent one year as a student at the Art Students League of New York. She brings the perspective of a scientist and skills of an artist to her work in patient care. She is the proud mother of three sons, and wife of Dr. David R. Kauvar, a gastroenterologist whom she met while at Harvard. She loves traveling, hiking and cooking with her husband and three sons.

Jenifer R. Lloyd, D.O.
A Board-certified dermatologist in private practice, Jenifer also serves as the Program Director, Dermatology Residency Program and University Hospitals Regional Hospitals—Richmond Medical Center in Richmond, Ohio, and holds multiple academic appointments at Northeast Ohio Medical University and Ohio University Heritage College of Osteopathic Medicine.

An accomplished researcher, author, and presenter in the dermatology industry, Jenifer lends her expertise in laser medicine and in-depth clinical knowledge of light therapy applications to the Sebacia Medical Advisory Board.

Jenifer received her D.O. at Des Moines University College of Osteopathic Medicine and completed residencies at the State University of New York at Buffalo and Case Western Reserve University. In December 2013, she completed a fellowship in academic medicine at Northeast Ohio Medical University, Internal Medicine-Dermatology.

E. Victor Ross, M.D., CAPT MC, USN (ret)
As the current Director of the Laser and Cosmetic Dermatology Center at Scripps Clinic in San Diego, Victor specializes in laser skin resurfacing, fractional laser applications, photodynamic therapy, non-ablative skin remodeling, laser treatment of leg veins, laser treatment of acne, and laser hair reduction in dark skinned patients. Victor is passionate about his life’s work, serving as associate editor of Lasers in Surgery and Medicine and having authored more than 85 clinical articles and seven book chapters.

He is presently investigating novel approaches in radiofrequency technology as well as conducting comparative trials of intense pulsed light and fractional laser sources in skin rejuvenation.

Victor obtained an M.D. from Tulane University School of Medicine where he was a junior year inductee into Alpha Omega Alpha; he graduated summa cum laude with a B.S. in Physics from Mississippi State University. Of note, Victor was the first Navy-sponsored fellow in Photomedicine and Lasers at Massachusetts General Hospital.

Diane Thiboutot, M.D.
Diane is a Professor of Dermatology at the Pennsylvania State University College of Medicine in Hershey, PA. She specializes in the care of patients with acne and rosacea and served as recent Past President of the American Acne and Rosacea Society.

As the Director of an active research program jointly supported by the NIH and industry, Diane has been investigating many high-interest areas including the regulation of sebum production, the mechanism of action of retinoids, and development of outcome measures for acne. She has also published numerous manuscripts and book chapters on these topics.

Diane received her M.D. and residency training in Dermatology at Pennsylvania State University College of Medicine. She currently serves as Associate Dean of Clinical and Translational Research Education at Penn State and is listed in the Best Doctors in America.

Clinical and Scientific Advisors:

James Leyden, M.D.
James is an Emeritus Professor Derm from the University of Pennsylvania with more than 40 years of experience, and multiple areas of research interests. He is best known for research in acne with approximately 400 publications and consultant to many companies.

Guy Webster, M.D., Ph.D.
Guy is a Clinical Professor of Dermatology at Thomas Jefferson University in Philadelphia, PA. He is active in numerous professional organizations and was the founding President of the American Acne and Rosacea Society, a Fellow of both the Pennsylvania Academy of Dermatology and the American Academy of Dermatology, and a member of the Society for Investigative Dermatology.

Guy's work has been published prolifically, with countless articles featured in the primary dermatology journals; he serves as a reviewer on many of these same respected publications. Additionally, Guy is on the editorial boards of Journal of the American Academy of Dermatology, Dermatology Online Journal, Clinics in Dermatology, and Skin Therapy Letter.

A highly esteemed lecturer on the national and international levels, Guy has also been named as one of America's Best Doctors, 2004-2008.

He received his education at the University of Pennsylvania, where he earned his Ph.D., M.D., and a B.A. in Molecular Biology and Genetics.

Naomi J Halas, D.Sc.
As the Director of the Rice Quantum Institute at Rice University, Naomi is a research and knowledge powerhouse. Her specialties span multiple academic disciplines, including Electrical and Computer Engineering, Physics and Astronomy, Biomedical Engineering, Nanophotonics, and Chemistry.

Naomi's contributions to Sebacia are invaluable, as she shares the findings of and insights from her research in design and fabrication of optically responsive nanostructures, nanophototics, and plasmonics. Her personal and professional mission is to understand the function and physical properties of new nanoscale objects at the microscopic and macroscopic levels and inncorporate them into unique applications that impact technology and society as a whole.

In 2000, she co-founded Nanospectra Biosciences, Inc. with Jennifer West to commercialize a unique nanoparticle-assisted photothermal ablation technology.

In addition to holding multiple patents on breakthrough nanoshell technologies, Naomi is a respected investigator and distinguished professor and has been repeatedly honored for her commitment in this field.

Jennifer L. West, Ph.D.
Jennifer recently joined the faculty at Duke University as a Fitzpatrick Family University Professor of Engineering and an esteemed member of the departments of Biomedical Engineering, Mechanical Engineering and Materials Science, Chemistry, and Cell Biology.

In her previous role, Jennifer served as Department Chair and Cameron Professor of Bioengineering at Rice University. As one of the founding members of Rice's Department of Bioengineering, she was instrumental in its development into a top 10 program over the past 16 years.

Jennifer's research focuses on the development of novel biofunctional material, including nanoparticle-based approaches to biophotonics therapeutics and diagnostics. In 2000, she co-founded Nanospectra Biosciences, Inc. with Naomi Halas to commercialize a unique nanoparticle-assisted photothermal ablation technology.

An accomplished researcher, author, and presenter in the dermatology industry, Jenifer lends her expertise in laser medicine and in-depth clinical knowledge of light therapy applications.

Dr. Girish “Gilly” S. Munavalli
A native of North Carolina, Dr. Gilly Munavalli is the medical director and owner of Dermatology, Laser & Vein Specialists of the Carolinas in Charlotte, NC. He also currently serves as Assistant Professor of Dermatology at the Wake Forest University Department of Dermatology and Clinical Assistant Professor in the Department of Medicine at UNC School of Medicine | Carolinas Medical Center. He previously spent 4 years on the clinical faculty of Dermatology at Johns Hopkins School of Medicine. Dr. Munavalli received his Bachelor of Science from the University of North Carolina-Chapel Hill, Masters of Health Science from the Johns Hopkins University School of Public Health, Doctorate of Medicine from Morehouse Medical School in Atlanta, Georgia, followed by internship training at the Mayo Clinic.

Dr. Munavalli trained in Dermatology at Emory University and later completed his Dermatologic Surgery fellowship in Mohs Micrographic Surgery & Cutaneous Oncology (for the treatment of facial skin cancers), Facial Reconstruction, Cosmetic Surgery and Laser Surgery at the University of California - San Francisco. He also completed a fellowship in phlebology & advanced laser surgery at the Maryland Laser, Skin & Vein Institute. Dr. Munavalli received his Board Certification in Dermatology in 2002. He has served as principal investigator in a broad range of clinical research trials including device development, investigational drugs, and FDA pivotal trials for both therapeutic & cosmetic procedures.

Dr. Munavalli has lectured extensively in both domestic & international forums. He is a recognized expert on many topics, including dermal fillers, laser resurfacing, acne scarring, body contouring, and varicose/spider vein treatments.

Jill S. Waibel, M.D.
Dr. Waibel is board certified by the American Board of Dermatology. She specializes in cutaneous laser surgery, general and cosmetic dermatology. She is currently the medical director and owner of the Miami Dermatology and Laser Institute in South Miami. Dr. Waibel is also the Subsection Chief of Dermatology at Baptist Hospital. In addition, Dr. Waibel serves as a Clinical Voluntary Assistant Professor at the University of Miami.

Dr. Waibel’s undergraduate degree is from Indiana University. She completed medical school and dermatology residency at the Wright State School of Medicine in Ohio where she was at the top of her class, graduating Alpha Omega Alpha. Dr. Waibel served as chief resident and went on to do three laser preceptorships.

She has received numerous awards for her contributions to medicine, including an award given by Surgeon General Koop. Dr. Waibel is also a recipient of The American Society of Dermatologic Surgery Cutting Research Award.

In her practice she has over 35 laser devices and treats a wide variety of cutaneous disease.

The treatment of scars by applying today’s latest cutaneous laser technologies is one of Dr. Waibel’s primary passions. She has successfully developed industry leading procedures and techniques with lasers. She works with a team that has developed patents related to laser and stem cells. Dr. Waibel is active in basic science clinical trials at the University of Miami and oversees a clinical trials division of Miami Dermatology and Research.

Dr. Waibel lectures nationally and internationally, and she has published over thirty peer-reviewed journal articles and several textbook chapters.

James Q. DelRosso
Dr. James Q. Del Rosso obtained a Bachelor of Science degree in pharmacy at St. John's University in Jamaica, New York in 1976. He then graduated from Ohio University College of Osteopathic Medicine in Athens, Ohio, in 1982 followed by a 3-year dermatology residency through Doctors Hospital, Plantation, Florida at Atlantic Skin Disease & Skin Surgery Association (Class of 1986) and is Board Certified in Dermatology by the American Osteopathic Association (AOA) and the American Osteopathic Board of Dermatology (AOBD) since February 1988. He also holds a Certificate of Added Qualification (CAQ) in Mohs Micrographic Surgery from the AOA and AOBD since 1995.

Starting in January 1997, Dr. Del Rosso joined Las Vegas Skin & Cancer Clinics in Las Vegas and Henderson, Nevada. Here he continued his practice of general medical and surgical dermatology and Mohs Micrographic Surgery that still remains very active, and has expanded his clinical research and educational activities significantly over the ensuing years. He is adjunct clinical professor, dermatology, at Touro University College of Osteopathic Medicine in Henderson, Nevada.

Dr. Del Rosso has been the clinical editor-in-chief of the Journal of Clinical and Aesthetic Dermatology since this journal's inception and has served for 4 years through 2012 as editor of the Yearbook of Dermatology and Dermatologic Surgery. In addition, he serves on the Editorial Board of Cutis and the Journal of Drugs in Dermatology, the latter as a frequent Guest Editor of the annual Acne & Rosacea issue for the past 6 years. He is also the co-director of the Fall Clinical Dermatology, Winter Clinical Dermatology,and Real World Dermatology for Residents meetings held each year. He is past-president of the American Osteopathic College of Dermatology, Council for Nail Disorders, American Society for Mohs Surgery, and most recently, the American Acne and Rosacea Society, where he has remained as chair of the Education Committee. Over the past 5 years, Dr. Del Rosso has served as dermatology residency program director at Valley Hospital Medical Center in Las Vegas, Nevada.

Samir Mitragotri, Ph.D.
Samir Mitragotri is a Professor of Chemical Engineering at the University of California, Santa Barbara (UCSB). He also serves as the Founding Director of UCSB's Center for Bioengineering and the Director of Translational Medical Research Laboratories. He received his Ph.D. from MIT and B.S. from Institute of Chemical Technology, Mumbai. Professor Mitragotri is a leading authority in fields of transdermal drug delivery, oral drug delivery and nanoparticle-based drug delivery systems. Professor Mitragotri has published about 175 publications in leading scientific journals. He is an inventor on over 80 pending or issued patents. Professor Mitragotri is an elected fellow of National Academy of inventors, American Institute of Medical and Biological Engineering, and American Association of Advancement in Science. He is also a recipient of American Institute of Chemical Engineering's Allan P. Colburn, Controlled Release Society's Young Investigator award and Technology Review Young Inventor award (TR35).


Sebacia to Present 12-Month Durability Data and New In Vivo Imaging Data for Sebacia Microparticles at ASLMS Annual Meeting 2019

March 26, 2019 (Duluth, GA) - Sebacia, Inc., a privately held, commercial stage dermatology and aesthetics company, today announced that new data from studies on the Company’s proprietary Sebacia Microparticles will be featured in three separate presentations during the 39th Annual Conference of the American Society for Laser Medicine and Surgery.

Read entire press release here
Sebacia EU Real-World Results Demonstrate 85% Durable Improvement in Acne at 12 Months

March 1, 2019 (Duluth, GA) - Sebacia, Inc., a privately held, commercial stage dermatology and aesthetics company, today announced new results from its real-world study in Europe evaluating Sebacia Microparticles for treatment of acne. The study demonstrated an average 85% improvement in facial acne at 12 months.

Read entire press release here
Sebacia to Present New 12-Month Durability Results from EU Real-World Acne Study at AAD Annual Meeting 2019

February 27, 2019 (Duluth, GA) - Sebacia, Inc., a privately held, commercial stage dermatology and aesthetics company, today announced that 12-month data from its real-world study in Europe evaluating Sebacia Microparticles for treatment of facial acne will be presented during the American Academy of Dermatology (AAD) 2019 Annual Meeting, being held March 1-5 in Washington, D.C. at the Walter E. Washington Convention Center.

Read entire press release here
Sebacia EU Real-World Results Demonstrate an Average 79% Improvement in Acne at 6 Months

October 11, 2018 (Duluth, GA) - Sebacia, Inc., a privately held, commercial stage dermatology and aesthetics company, today announced that its real-world, pre-conditioning registry trial in Europe demonstrated that the combination of pre-conditioning followed by Sebacia Microparticles led to an average 79% improvement in facial acne through six months of follow-up.

Read entire press release here
Sebacia Highlights Oral Presentation of EU Real-World Pre-Conditioning Study Results at ASDS Annual Meeting 2018

October 8, 2018 (Duluth, GA) - Sebacia, Inc., a privately held, commercial stage dermatology and aesthetics company, today announced that results from its real-world pre-conditioning study in Europe evaluating Sebacia Microparticles for treatment of facial acne has been accepted for an oral presentation during the American Society for Dermatologic Surgery (ASDS) 2018 Annual Meeting.

Read entire press release here
U.S. FDA Clears Sebacia Microparticles for the Treatment of Mild to Moderate Inflammatory Acne

September 17, 2018 (Duluth, GA) - Sebacia, Inc., a privately held, clinical and commercial stage dermatology and aesthetics company, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance for its lead product, Sebacia Microparticles.

Read entire press release here
Sebacia Announces Favorable Ruling by U.S. Court of Appeals for the Federal Circuit Regarding Patent Interference Proceedings with Sienna Biopharmaceuticals, Inc.

May 7, 2018 (Duluth, GA) - Sebacia, Inc., a privately held, clinical and commercial stage dermatology and aesthetics company, today announced a precedential ruling from the U.S. Court of Appeals for the Federal Circuit. The ruling relates to a patent interference proceeding between The General Hospital Corporation (GHC, the owner of certain patents licensed by Sebacia) and Sienna Biopharmaceuticals, Inc.

Read entire press release here
Sebacia Announces $36 Million Equity and Debt Financing to Advance Breakthrough In-Office Procedure for Acne

July 25, 2017 (Duluth, GA) - Sebacia, Inc., a privately held, clinical and commercial stage dermatology and aesthetics company, today announced that the company has completed a $20 million Series D financing led by existing investors Versant Ventures, Domain Associates, Accuitive Medical Ventures and Partners Healthcare Innovation Fund.

Read entire press release here


I am a:
How did you learn about Sebacia?